Is trazodone effective for reducing nightmares in patients with post‑traumatic stress disorder?

Trazodone Shows Modest Benefit for PTSD Nightmares but Evidence is Limited

Trazodone may reduce nightmare frequency in PTSD patients based on retrospective data, but the evidence is weak and comes from a single uncontrolled study—consider it a reasonable option when first-line treatments fail, while being vigilant about significant side effects including priapism. 1

Evidence Quality and Strength

The American Academy of Sleep Medicine 2018 position paper 1 reviews trazodone for PTSD nightmares, but the evidence base is notably thin:

• Only one retrospective cohort study of 74 male veterans forms the primary evidence
• No randomized controlled trials exist for trazodone specifically targeting PTSD nightmares
• The FDA label 2 indicates trazodone is approved only for major depressive disorder in adults, not for PTSD or nightmares

Clinical Effectiveness Data

In the single retrospective study reviewed in the guideline 1:

• 60 of 74 patients (81%) tolerated an effective dose
• Nightmare frequency decreased from 3.3 ± 1.7 to 1.3 ± 1.4 nights/week in responders
• Mean effective dose was 212 mg/day (range 50-200 mg for 70% of patients)
• This represents approximately a 60% reduction in nightmare frequency

Critical Safety Concerns

The side effect profile is concerning and must be discussed upfront:

• Priapism occurred in 5 of 74 patients (6.8%) in the guideline-cited study 1
• One research study 3 reported priapism in 9 of 74 patients (12%)—higher than expected
• 14 patients (19%) discontinued due to intolerable side effects including:
  • Daytime sedation (most common)
  • Dizziness
  • Paradoxically more vivid nightmares (1 patient)
  • Severe agitation (1 patient)

Common pitfall: Clinicians often fail to explicitly warn male patients about priapism risk. This must be discussed before prescribing, as it constitutes a urological emergency requiring immediate treatment.

Clinical Algorithm for Use

When to consider trazodone:

1. After first-line treatments have been tried: Image rehearsal therapy (trauma-focused CBT) should be attempted first, as psychotherapy has stronger evidence 1
2. When prazosin is contraindicated or ineffective: Recent evidence suggests prazosin may be more effective for PTSD nightmares 4, 5, 6, though this remains debated
3. When insomnia coexists with nightmares: Trazodone may address both symptoms simultaneously 3, 7, 8

Dosing approach:

• Start at 50 mg at bedtime
• Titrate gradually to 200-400 mg based on response
• Take shortly after a meal or light snack to reduce side effects
• Allow 2-3 months for full effect on nightmares (sleep improves first) 9

Comparison to Alternatives

The same guideline 1 notes:

• Clonazepam showed no benefit over placebo in a small controlled trial
• Venlafaxine showed no benefit for PTSD nightmares in pooled analysis
• Prazosin has more recent supportive evidence 4, 5, 6, though earlier large trials were negative

Bottom Line for Clinical Practice

Trazodone represents a third-line option for PTSD nightmares when:

• Trauma-focused psychotherapy has been inadequate
• Other pharmacological options (prazosin, SSRIs for overall PTSD) have failed or are contraindicated
• The patient understands and accepts the risk-benefit profile, particularly priapism risk in males

The evidence supporting trazodone is substantially weaker than for psychotherapy 1, consisting only of retrospective uncontrolled data. However, in real-world practice where access to specialized trauma therapy may be limited and nightmares are severely impairing quality of life, a time-limited trial (3-6 months) is reasonable with close monitoring for adverse effects.